Skip to main content
Book
Identification of peplomer cleavage site mutations arising during persistence of MHV-A59
Advances in Experimental Medicine and Biology
  • James L. Gombold
  • Susan T. Hingley, Philadelphia College of Osteopathic Medicine
  • Susan R. Weiss
Document Type
Book
Publication Date
1-1-1994
Disciplines
Abstract

Primary mouse glial cell cultures were infected with mouse hepatitis virus strain A59 (MHV-A59) and maintained over an 18 week period. Viruses isolated from these cultures 16-18 weeks postinfection produce small plaques on fibroblasts and cause only minimal levels of cell-to-cell fusion at times when wild type causes nearly complete cell fusion. However, when mutant- infected cultures were examined 24-36 hours postinfection approximately 90% of the cells were in syncytia showing that the fusion defect is not absolute but rather delayed. Addition of trypsin to mutant-infected cultures enhanced cell fusion a small (2- to 5-fold) but significant degree. Sequencing of portions of the spike genes of six fusion-defective mutants revealed that all contained the same single nucleotide mutation resulting in a substitution of aspartic acid for histidine in the spike cleavage signal. Mutant virions contained only the 180 kDa form of spike protein suggesting that this mutation prevented the normal proteolytic cleavage of the 180 kDa protein into the 90 kDa subunits. Examination of revertants of the mutants supports this hypothesis. Replacement of the negatively-charged aspartic acid with either the wild type histidine or a non-polar amino acid was associated with the restoration of spike protein cleavage and cell fusion.

Comments

This chapter was published in Advances in Experimental Medicine and Biology, Volume 342, Pages 157-163.

The published version is available at http://dx.doi.org/10.1007/978-1-4615-2996-5_25 .

Copyright © 1994 Springer.

Citation Information
James L. Gombold, Susan T. Hingley and Susan R. Weiss. Identification of peplomer cleavage site mutations arising during persistence of MHV-A59. Advances in Experimental Medicine and Biology Vol. 342 (1994) p. 157 - 163
Available at: http://works.bepress.com/susan_hingley/22/